{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:44:53Z","timestamp":1787071493175,"version":"build-2736575974"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Dipeptidyl peptidase 4 (DPP4) inhibitors are widely used in type 2 diabetes mellitus (T2DM) patients but the data available in existing clinical trial programmes on DPP4 inhibitors include limited number of patients from India. Hence, this study attempted to understand usage, efficacy and safety of saxagliptin as first add-on after metformin in Indians with T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology:<\/jats:title>\n                    <jats:p>It was a multicenter, prospective, non-interventional and observational study planned to enrol T2DM patients who were inadequately controlled with metformin alone and had been recently (i.e., within past 15 days) prescribed saxagliptin as an add-on to metformin. Type 1 diabetes mellitus, use of glucose lowering drugs apart from metformin or saxagliptin, pregnancy, lactation, and medical condition, which could interfere with safe completion of the study were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 1109 participants (658 men and 451 women) with mean \u00b1 SD age of 51.17 \u00b1 11.85 years were enrolled from 50 centres throughout India. Significant reduction was observed in mean \u00b1 SD change of HbA1c as \u2212 0.86% \u00b1 1.76 from baseline to after 3 months of therapy (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). The quality of life assessed by World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire was reported to be \u201cgood\u201d or \u201cneither good nor bad\u201d by majority of the participants at baseline and after 3 months of treatment. A total of 15 adverse events (AEs) were reported in the study, however, no serious adverse event (SAE) occurred during the study. All AEs were of mild intensity and did not require any intervention.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Overall, saxagliptin in combination with metformin was generally well tolerated in Indian T2DM patients and new safety event identified is an increased risk of hospitalisation in heart failure patients. This study is also registered on Clinicaltrials.gov (NCT02588859).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijem.ijem_56_19","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T06:58:27Z","timestamp":1564383507000},"page":"312-317","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Experience of Saxagliptin as First Add-on after Metformin in Indian Type 2 Diabetes Patients: A Non-interventional, Prospective, Observational Study (ONTARGET-INDIA)"],"prefix":"10.4103","volume":"23","author":[{"given":"Sanjay","family":"Kalra","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Bharti Research Institute of Diabetes and Endocrinology, Karnal, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Bajaj","sequence":"additional","affiliation":[{"name":"Department of Medicine, Moti Lal Nehru Medical College, Allahabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Unnikrishnan","sequence":"additional","affiliation":[{"name":"Department of Clinical Diabetology and Endocrinology, Chellaram Diabetes Institute, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manash P.","family":"Baruah","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Excel Center, Maya Ville, Barthakur Mill Road, Ulubari, Guwahati, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Sahay","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Osmania General Hospital, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Hardik","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, AstraZeneca Pharma India Ltd, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, AstraZeneca Pharma India Ltd, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260327","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ndt\/gfu405","article-title":"Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease","volume":"31","author":"Karalliedde","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"R2-20260327","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.2337\/dc14-S081","article-title":"Diagnosis and classification of diabetes mellitus","volume":"37","author":"Association","year":"2014","journal-title":"Diabetes Care"},{"key":"R3-20260327","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4103\/2230-8210.183480","article-title":"Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?","volume":"20","author":"Chawla","year":"2016","journal-title":"Indian J Endocr Metab"},{"key":"R6-20260327","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s13167-010-0010-9","article-title":"Diabetes mellitus: New challenges and innovative therapies","volume":"1","author":"Sena","year":"2010","journal-title":"EPMA J"},{"key":"R7-20260327","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fendo.2017.00006","article-title":"Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management","volume":"8","author":"Chaudhury","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R8-20260327","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","article-title":"Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"key":"R9-20260327","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"R10-20260327","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4103\/2230-8210.141319","article-title":"Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions","volume":"18","author":"Singh","year":"2014","journal-title":"Indian J Endocr Metab"},{"key":"R11-20260327","first-page":"18816","article-title":"Efficacy and safety of saxagliptin and metformin as initial combination therapy in patients with type 2 diabetes: A meta-analysis","volume":"9","author":"Tan","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"R12-20260327","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s13300-016-0189-4","article-title":"Systematic literature review of DPP-4 inhibitors in patients with type 2 diabetes mellitus and renal impairment","volume":"7","author":"Thomas","year":"2016","journal-title":"Diabetes Ther"},{"key":"R13-20260327","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/DMSO.S117982","article-title":"Emerging use of combination therapies for the management of type 2 diabetes\u2013Focus on saxagliptin and dapagliflozin","volume":"10","author":"Yu","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R14-20260327","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s13300-016-0200-0","article-title":"Blood glucagon levels predict the hemoglobin A1c response to saxagliptin in patients with type 2 diabetes inadequately controlled with metformin","volume":"7","author":"Liu","year":"2016","journal-title":"Diabetes Ther"},{"key":"R15-20260327","first-page":"20","article-title":"US cost-effectiveness of saxagliptin in type 2 diabetes mellitus","volume":"4","author":"Bergenheim","year":"2012","journal-title":"Am J Pharm Benefits"},{"key":"R16-20260327","doi-asserted-by":"crossref","first-page":"A180","DOI":"10.1016\/j.jval.2012.03.974","article-title":"PDB53 cost-effectiveness of saxagliptin (Onglyza\u00ae) in type 2 diabetes in South Africa","volume":"15","author":"Juarez-Garcia","year":"2012","journal-title":"Value Health"},{"key":"R17-20260327","doi-asserted-by":"crossref","first-page":"e0167190","DOI":"10.1371\/journal.pone.0167190","article-title":"Cost-effectiveness of saxagliptin versus acarbose as second-line therapy in type 2 diabetes in China","volume":"11","author":"Gu","year":"2016","journal-title":"PLoS One"},{"key":"R18-20260327","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: An old but still the best treatment for type 2 diabetes","volume":"5","author":"Rojas","year":"2013","journal-title":"Diabetol Metab Syndr"},{"key":"R20-20260327","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1185\/03007995.2012.681639","article-title":"Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and\/or sulphonylurea","volume":"28","author":"Lund","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"3 Suppl 2","key":"R21-20260327","first-page":"S8","article-title":"The physiologic role of incretin hormones: Clinical applications","volume":"110","author":"Cefalu","year":"2010","journal-title":"J Am Osteopath Assoc"},{"key":"R22-20260327","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1463-1326.2006.00704.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial","volume":"9","author":"Nauck","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"R23-20260327","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","article-title":"Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats","volume":"48","author":"Xu","year":"1999","journal-title":"Diabetes"},{"key":"R24-20260327","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2337\/diabetes.51.5.1443","article-title":"Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4","volume":"51","author":"Tourrel","year":"2002","journal-title":"Diabetes"},{"key":"R25-20260327","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4158\/EP161682.CS","article-title":"Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2017 executive summary","volume":"23","author":"Garber","year":"2017","journal-title":"Endocr Pract"},{"key":"R26-20260327","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4093\/dmj.2014.38.3.211","article-title":"The effect of DPP-4 inhibitors on metabolic parameters in patients with type 2 diabetes","volume":"38","author":"Choe","year":"2014","journal-title":"Diabetes Metab J"},{"key":"R27-20260327","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4103\/0976-500X.85934","article-title":"Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus","volume":"2","author":"Dave","year":"2011","journal-title":"J Pharmacol Pharmacother"},{"key":"R28-20260327","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3810\/pgm.2010.05.2144","article-title":"Type 2 diabetes comorbidities and treatment challenges: Rationale for DPP-4 inhibitors","volume":"122","author":"Hollander","year":"2010","journal-title":"Postgrad Med"},{"key":"R29-20260327","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s12325-015-0262-9","article-title":"Utility of saxagliptin in the treatment of type 2 diabetes: Review of efficacy and safety","volume":"32","author":"Jain","year":"2015","journal-title":"Adv Ther"},{"key":"R30-20260327","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/DMSO.S16361","article-title":"Patient considerations and clinical utility of a fixed dose combination of saxagliptin\/metformin in the treatment of type 2 diabetes","volume":"4","author":"Derosa","year":"2011","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R31-20260327","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1089\/dia.2011.0204","article-title":"Dipeptidyl peptidase-4 inhibitors: 3 years of experience","volume":"14","author":"Derosa","year":"2012","journal-title":"Diabetes Technol Ther"},{"key":"R32-20260327","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s13300-013-0028-9","article-title":"Adding saxagliptin to metformin extended release (XR) or uptitration of metformin XR: Efficacy on daily glucose measures","volume":"4","author":"Neutel","year":"2013","journal-title":"Diabetes Ther"},{"key":"R34-20260327","doi-asserted-by":"crossref","first-page":"608","DOI":"10.4103\/0250-474X.59541","article-title":"Gliptins: A new class of oral antidiabetic agents","volume":"71","author":"Seshadri","year":"2009","journal-title":"Indian J Pharm Sci"},{"key":"R35-20260327","doi-asserted-by":"crossref","first-page":"S859","DOI":"10.1016\/j.dsx.2017.07.006","article-title":"Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus","volume":"11","author":"de Souza Cazarim","year":"2017","journal-title":"Diabetes Metab Syndr"},{"key":"R36-20260327","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12913-018-2860-0","article-title":"Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes","volume":"18","author":"Kwon","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"R37-20260327","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/dmrr.1114","article-title":"Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus","volume":"26","author":"Scheen","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"key":"R38-20260327","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/j.1742-1241.2010.02510.x","article-title":"Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: A 52-week randomised controlled trial","volume":"64","author":"Goke","year":"2010","journal-title":"Int J Clin Pract"},{"key":"R39-20260327","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/dc14-1142","article-title":"Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"R40-20260327","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1463-1326.2011.01540.x","article-title":"Saxagliptin and sitagliptin in adult patients with type 2 diabetes: A systematic review and meta-analysis","volume":"14","author":"Gerrald","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"R41-20260327","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s13300-013-0045-8","article-title":"Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin","volume":"4","author":"Tatosian","year":"2013","journal-title":"Diabetes Ther"},{"key":"R42-20260327","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1185\/03007995.2014.880674","article-title":"Saxagliptin versus glipizide as add-on therapy to metformin: Assessment of hypoglycemia","volume":"30","author":"Mintz","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"R43-20260327","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.diabres.2011.07.035","article-title":"Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial","volume":"94","author":"Yang","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"R44-20260327","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1758-5996-6-69","article-title":"Efficacy and safety of vildagliptin, saxagliptin or sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents","volume":"6","author":"Li","year":"2014","journal-title":"Diabetol Metab Syndr"},{"key":"R45-20260327","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/dom.12234","article-title":"A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea","volume":"16","author":"Moses","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"R46-20260327","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"R47-20260327","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"R48-20260327","first-page":"1003","article-title":"[SAVORTIMI 53 - Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus]","volume":"59","author":"Spinar","year":"2013","journal-title":"Vnitr Lek"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/02223308-201923030-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:46:54Z","timestamp":1787068014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02223308-201923030-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_56_19","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}